MA56607A1 - Méthodes de traitement de troubles dépressifs - Google Patents
Méthodes de traitement de troubles dépressifsInfo
- Publication number
- MA56607A1 MA56607A1 MA56607A MA56607A MA56607A1 MA 56607 A1 MA56607 A1 MA 56607A1 MA 56607 A MA56607 A MA 56607A MA 56607 A MA56607 A MA 56607A MA 56607 A1 MA56607 A1 MA 56607A1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- depressive disorders
- treating depressive
- compound
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Selon certains modes de réalisation, la présente invention concerne des méthodes et des utilisations pour traiter des troubles dépressifs chez un être humain, les méthodes comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace de n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3-diméthylbutanamide (composé a), à la personne nécessitant un tel traitement. La présente invention concerne également diverses méthodes améliorées de thérapie et d'administration du composé a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932724P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/059481 WO2021092439A1 (fr) | 2019-11-08 | 2020-11-06 | Méthodes de traitement de troubles dépressifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56607A1 true MA56607A1 (fr) | 2022-10-31 |
Family
ID=73643360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56607A MA56607A1 (fr) | 2019-11-08 | 2020-11-06 | Méthodes de traitement de troubles dépressifs |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210161886A1 (fr) |
| EP (1) | EP4054580A1 (fr) |
| JP (1) | JP2022553569A (fr) |
| KR (1) | KR20220098746A (fr) |
| CN (1) | CN114667146A (fr) |
| AU (1) | AU2020380961A1 (fr) |
| BR (1) | BR112022008580A2 (fr) |
| CA (1) | CA3155812A1 (fr) |
| CL (1) | CL2022001102A1 (fr) |
| CO (1) | CO2022008001A2 (fr) |
| CR (1) | CR20220250A (fr) |
| IL (1) | IL292678A (fr) |
| MA (1) | MA56607A1 (fr) |
| MX (1) | MX2022005490A (fr) |
| PE (1) | PE20221766A1 (fr) |
| TW (1) | TW202128162A (fr) |
| WO (1) | WO2021092439A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117015379A (zh) * | 2021-02-09 | 2023-11-07 | 泽农医药公司 | 用于治疗癫痫发作病症的联合疗法 |
| CA3207191A1 (fr) | 2021-02-09 | 2022-08-18 | Simon Neil PIMSTONE | Ouvreur de canaux potassiques sensibles a la tension destine a etre utilise dans le traitement de l'anhedonie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| EP2061465B1 (fr) * | 2006-08-23 | 2013-04-10 | Valeant Pharmaceuticals International | Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique |
-
2020
- 2020-11-06 EP EP20816351.9A patent/EP4054580A1/fr active Pending
- 2020-11-06 KR KR1020227017725A patent/KR20220098746A/ko unknown
- 2020-11-06 JP JP2022524695A patent/JP2022553569A/ja active Pending
- 2020-11-06 PE PE2022000702A patent/PE20221766A1/es unknown
- 2020-11-06 BR BR112022008580A patent/BR112022008580A2/pt unknown
- 2020-11-06 MA MA56607A patent/MA56607A1/fr unknown
- 2020-11-06 AU AU2020380961A patent/AU2020380961A1/en active Pending
- 2020-11-06 MX MX2022005490A patent/MX2022005490A/es unknown
- 2020-11-06 CA CA3155812A patent/CA3155812A1/fr active Pending
- 2020-11-06 TW TW109138929A patent/TW202128162A/zh unknown
- 2020-11-06 WO PCT/US2020/059481 patent/WO2021092439A1/fr active Application Filing
- 2020-11-06 CN CN202080077815.3A patent/CN114667146A/zh active Pending
- 2020-11-06 CR CR20220250A patent/CR20220250A/es unknown
- 2020-11-09 US US17/093,183 patent/US20210161886A1/en active Pending
-
2022
- 2022-04-29 CL CL2022001102A patent/CL2022001102A1/es unknown
- 2022-05-02 IL IL292678A patent/IL292678A/en unknown
- 2022-06-06 CO CONC2022/0008001A patent/CO2022008001A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054580A1 (fr) | 2022-09-14 |
| CO2022008001A2 (es) | 2022-06-10 |
| JP2022553569A (ja) | 2022-12-23 |
| PE20221766A1 (es) | 2022-11-11 |
| KR20220098746A (ko) | 2022-07-12 |
| CA3155812A1 (fr) | 2021-05-14 |
| CR20220250A (es) | 2022-08-19 |
| IL292678A (en) | 2022-07-01 |
| WO2021092439A1 (fr) | 2021-05-14 |
| AU2020380961A1 (en) | 2022-05-26 |
| US20210161886A1 (en) | 2021-06-03 |
| TW202128162A (zh) | 2021-08-01 |
| CN114667146A (zh) | 2022-06-24 |
| MX2022005490A (es) | 2022-08-10 |
| CL2022001102A1 (es) | 2023-01-27 |
| BR112022008580A2 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| HUP0004170A2 (hu) | Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére | |
| MA52569B1 (fr) | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant | |
| MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
| MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| ATE119520T1 (de) | Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung. | |
| DE60125541D1 (de) | Neue nicht psychotropische cannabinoide | |
| ATE401874T1 (de) | Verabreichung von capsaicinoiden | |
| MA44764A (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| ATE259230T1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
| DE60140871D1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| MA51627B1 (fr) | Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés | |
| HUP9802971A1 (hu) | Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| MA27539A1 (fr) | Nouvelle combinaison synergique contenant du roflumilast et du formoterol | |
| BG98827A (en) | Pharmaceutical composition and method for its preparation | |
| WO2001091796A8 (fr) | Methodes, composes et compositions permettant de traiter la goutte | |
| ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| DE69512940T2 (de) | N-hydroxy-harnstoff-derivate als entzündunghemmende mittel | |
| ATE293972T1 (de) | Behandlung von chronischen schmerzen | |
| MA56958A1 (fr) | Utilisation d'un agent d'ouverture du canal potassique kv7 pour le traitement de la douleur | |
| EA200401295A1 (ru) | Статиновая терапия для усиления поддержания когнитивной функции | |
| DE69230790D1 (de) | Arzneimittel zur Behandlung von durch Babesia verursachten Protozoeninfektionen |